Welcome to our dedicated page for Cardlytics SEC filings (Ticker: CDLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cardlytics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cardlytics's regulatory disclosures and financial reporting.
Cardlytics, Inc. director and CEO Amit Gupta reported a mix of RSU conversions and open-market sales of Common Stock. On July 1, 2026, he converted 18,750 and 12,500 Restricted Stock Units into the same number of Common Stock shares at a conversion price of $0.00 per share. On July 2, 2026 and July 6, 2026, he then sold 6,498 and 9,640 Common Stock shares, respectively, at weighted average prices of about $4.40 per share. Following these transactions, Gupta directly holds 113,850 Common Stock shares. The filing notes a 1-for-10 reverse stock split effective June 5, 2026, and explains that RSU awards continue to vest in scheduled quarterly installments through April 1, 2027 and April 1, 2028, subject to ongoing employment.
Cardlytics, Inc.’s Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer reported a combination of RSU vesting and a related share sale. On July 1, 2026, he exercised restricted stock units that delivered a total of 4,719 shares of Common Stock. On July 2, 2026, he sold 2,151 shares of Common Stock at a weighted average price of $4.395 per share, with footnotes stating the sale was made solely to cover tax withholding obligations from the RSU share delivery. Following these transactions, he directly holds 19,353 shares of Cardlytics common stock, with no remaining derivative positions shown in this filing.
Amit Gupta filed a Form 144 reporting proposed sales and recent dispositions of Common shares of CDLX. The filing lists 9,640 shares proposed to be sold on 07/02/2026 (listed as Restricted Stock Vesting / Compensation) and discloses prior dispositions of 69,833 shares on 04/06/2026 and 6,498 shares on 07/02/2026.
Cadre Logistics, Inc. filed a Rule 144 notice reporting planned and recent transfers of Common Stock. The filing lists 6,498 shares of restricted stock vesting on 07/01/2026 (compensation) and two transfers by Amit Gupta of 54,225 shares on 04/02/2026 and 69,833 shares on 04/06/2026, with dollar values shown in the record.
Cardlytics, Inc. reported that Nasdaq notified the company its common stock has closed below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5550(a)(2). The company has until November 30, 2026 to restore a bid price of at least $1.00 for ten consecutive business days or face possible delisting, subject to potential extensions and appeal rights.
To address this and modify its capital structure, Cardlytics approved a 1-for-10 reverse stock split and reduced authorized common shares from 100,000,000 to 10,000,000, effective at 5:00 p.m. Eastern Time on June 5, 2026. Every 10 shares will convert into one share, with no fractional shares issued; cash will be paid instead. Shares outstanding will move from 58,078,634 as of June 1, 2026 to approximately 5,807,863, with proportional adjustments to convertible notes, stock options, restricted stock units, and equity plan reserves. The stock will begin trading on a split-adjusted basis on June 8, 2026.
Cardlytics, Inc. director Srishti A. Gupta reported routine equity compensation activity. On May 20, 2026, Gupta exercised 11,000 restricted stock units, receiving the same number of common shares at a price of $0.00 per share. This increased her directly held common stock to 17,148 shares after the transaction.
On the same date, Gupta received a new grant of 11,000 restricted stock units, each representing a contingent right to one share of Cardlytics common stock or its cash equivalent. According to the terms, these new RSUs vest in full on the one-year anniversary of the grant if she remains a director on that date.
Cardlytics director Francis Jonathan Edward reported routine equity compensation changes. On May 20, 2026, he exercised 11,000 restricted stock units into the same number of common shares and received a new grant of 11,000 RSUs. He now directly holds 26,310 common shares and 11,000 RSUs, which will vest one year after grant if he remains a director.
Cardlytics director Scott A. Hill increased his equity exposure through compensation-related transactions. He exercised 11,000 restricted stock units into 11,000 shares of common stock, and separately received a new grant of 11,000 RSUs that will vest in full after one year of continued board service. Following these moves, he holds 68,748 shares of common stock directly and 11,000 RSUs representing a contingent right to additional shares or their cash equivalent.
Cardlytics, Inc. director Andre J. Fernandez increased his equity-based holdings through routine compensation activity. He exercised 11,000 restricted stock units into 11,000 shares of common stock after they vested in full on the one-year anniversary of their grant. Following this exercise, he directly owns 26,310 shares of common stock.
On the same date, he received a new grant of 11,000 restricted stock units, each representing a right to receive one share of Cardlytics common stock or its cash equivalent at the company’s election. These new RSUs will vest in full on the one-year anniversary of the grant, assuming he continues to serve as a director.